NCT00621452 - Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2014

Conditions

B-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia

Interventions

BIOLOGICAL

therapeutic autologous lymphocytes

Given IV

DRUG

cyclophosphamide

Given IV

BIOLOGICAL

aldesleukin

Given subcutaneously

GENETIC

polymerase chain reaction

Correlative studies

GENETIC

gene rearrangement analysis

Correlative studies

PROCEDURE

lymph node biopsy

Optional correlative studies

BIOLOGICAL

genetically engineered lymphocyte therapy

Receive genetically modified T cells

PROCEDURE

bone marrow aspiration

Optional correlative studies

OTHER

flow cytometry

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

enzyme-linked immunosorbent assay

Correlative studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER